|
Post by celo on Jun 3, 2019 9:16:51 GMT -5
Does it mean anything that Biomm stock is up 6 to 7% on the news? It would be nice to see it popping based on Approval of Afrezza. Biomm has a bigger market cap than Mannkind (yahoo finance) unless its Brazil's currency.
|
|
|
Post by peppy on Jun 3, 2019 9:20:07 GMT -5
Brazil has some 210mn people where class A+B of population (rich or almost rich people) accounting for around 35% or almost 75mn people. > 50 mn residents have a private health insurance that is in my view the potential target of Afrezza in Brazil.If MNKD can pick up 4000 type one rich Brazilians that would be a great start. The thing that strikes me regarding Brazil and South America in General , is they are money talks societies and the private pay is still the way. The physicians there are much looser with the script.
|
|
|
Post by casualinvestor on Jun 3, 2019 9:23:43 GMT -5
Afrezza is approved in the US, but not getting enough traction that results in sales. At least not enough to turn the corner to profitability (yet). This is due to many reasons.
Afrezza is now approved in Brazil. We will see about traction there, but it's a given that it will have to be sold for much less $$/script.
However, any new sales above the cost of manufacture would be a Good Thing
|
|
|
Post by matt on Jun 3, 2019 9:25:29 GMT -5
I am very pleasantly STUNNED!! Does anyone know if the level of corruption in the Brazilian public healthcare system is comparable to the FDA or is there a reasonable belief that Afrezza will actually be available to patients without having to fight for it? Brazil, like most South American countries, has a fair degree of corruption but that does not make doing business impossible so long as there is strong lobbying presence in the government agencies. The level of healthcare funding is, by far, the biggest obstacle. For the product lines that I have experience with, the market prices in Brazil run about 20-25% of that obtainable in the US, which is almost certainly below MNKD's variable manufacturing cost. In certain segments of the medical industry it is normal practice to bribe doctors in return for writing prescriptions. Bribing physicians is often the only way to get sales in markets where the government doesn't pay enough for providing treatment. A number of major companies, including Zimmer-Biomet, Eli Lilly, Olympus, and Orthofix have all been fined by the SEC under the Foreign Corrupt Practices Act for paying bribes to physicians.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 3, 2019 9:28:40 GMT -5
Brazil has some 210mn people where class A+B of population (rich or almost rich people) accounting for around 35% or almost 75mn people. > 50 mn residents have a private health insurance that is in my view the potential target of Afrezza in Brazil. They have 12MM Diabetics as of today and probably 3MM on Insulin?
|
|
|
Post by letitride on Jun 3, 2019 9:34:17 GMT -5
Does Brazil require a script for insulin?
|
|
|
Post by peppy on Jun 3, 2019 9:39:03 GMT -5
Brazil has some 210mn people where class A+B of population (rich or almost rich people) accounting for around 35% or almost 75mn people. > 50 mn residents have a private health insurance that is in my view the potential target of Afrezza in Brazil. They have 12MM Diabetics as of today and probably 3MM on Insulin? yes, and as Matt pointed out, we will get scripts from a few of the very rich. by very rich, I mean the kind of people that live in beautiful homes with body guards and their type one children. They will private pay. That is the gig down there. They do not have the same health insurance coverage as the US. For instance the employer probably does not provide health insurance. That is how I think it works. Which is not to say, excellent surgeons etc can not be found. A double negative...and I am not going to rework that sentence.
|
|
|
Post by mannmade on Jun 3, 2019 10:10:16 GMT -5
To add to what Peppy said the more volume of cartridges produced the lower the average cost per carteidge. Such that if mnkd breaks even in what it produces for Brazil it will still raise the margin of profit for each cartridge sold in US.
|
|
|
Post by stockwhisperer on Jun 3, 2019 10:17:13 GMT -5
Certainly like that the PR refers to it as, ‘the only orally inhaled ultra-rapid acting mealtime insulin approved by ANVISA in Brazil.’ People everywhere will see that in the news - great for awareness here in the U.S. - anywhere / we can legally get it. All good.
|
|
|
Post by slugworth008 on Jun 3, 2019 10:18:28 GMT -5
You know it would be nice if there was a link to this article on www.mannkindcorp.com somewhere. Or a press release. You mean if someone in PR or IR actually did their job #whoknowwhoimean
|
|
|
Post by u1682002 on Jun 3, 2019 10:40:45 GMT -5
Certainly like that the PR refers to it as, ‘the only orally inhaled ultra-rapid acting mealtime insulin approved by ANVISA in Brazil.’ People everywhere will see that in the news - great for awareness here in the U.S. - anywhere / we can legally get it. All good. It is certainly good news. My question is whether or not Afrezza is indeed approved as a category of "Ultra-rapid" insulin in Brazil. I remember it is not approved as "Ultra-rapid" insulin in US. Can someone confirm if I am right? Thanks.
|
|
|
Post by sportsrancho on Jun 3, 2019 11:04:49 GMT -5
ST..
@lemonhead1 Hopefully they are proactive, and have a team assembled to go to Brazil to help the patients with the proper dosing of the drug. Learn from the mistakes that were made here in the USA.
|
|
|
Post by radgray68 on Jun 3, 2019 11:05:13 GMT -5
Now, launch in Brazil isn't until December. But, how long before people start complaining about the sluggish sales in Brazil? Anyone want to start a pool? O.K. I'm setting my egg timer, though.
|
|
|
Post by tw12 on Jun 3, 2019 11:08:36 GMT -5
In anticipation of what will soon be the growing curiosity of Brazilian diabetics, it seems a good idea for the MannKind team to add asap a section on www.afrezza.com in Portuguese. Give potential customers the compliment of some early product information and help create the market. Low cost, high return. To compliment whatever Biomm might publish. On that count, why not make the same compliment to Indian diabetics, with an introductory section in Hindi, Bengali, Telugu and Marathi (four most popular languages in India), all in the interest of letting local folks know we take them seriously.
|
|
|
Post by mannmade on Jun 3, 2019 11:13:23 GMT -5
They should have the complete mnkd website in the most commonly spoken language(s) of every country Afrezza is sold in. That includes Spanish here in the states.
|
|